Watson to Host and Webcast Investment Community Meeting at American Urological Association Annu... (

Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting

Date:4/22/2009

- Company to Highlight Data for its Two Newest Urological Products -

CORONA, Calif., April 22 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a global leader in the development and distribution of pharmaceuticals, announced today that management will host and webcast a meeting for the investment community at the American Urological Association (AUA) Annual Meeting taking place in Chicago, Illinois, April 25-30, 2009.

The company will be hosting the meeting to review new data on its two newest brands, RAPAFLO (silodosin) and GELNIQUE (oxybutynin chloride) Gel 10%, including:

Two post-hoc analyses of Phase 3 trials for RAPAFLO(TM) (silodosin): On efficacy, specifically for irritative and obstructive symptoms; and retrograde ejaculation - a harmless side effect of treatment - as an indicator of treatment efficacy. Reviewed by Herbert Lepor, M.D., Department of Urology, New York University School of Medicine, NY
The efficacy, safety and tolerability of GELNIQUE(TM) (oxybutynin chloride) Gel 10% versus placebo from Phase 3 trials. Reviewed by Roger R. Dmochowski, M.D., Department of Urologic Surgery, Vanderbilt University School of Medicine, Nashville, TN

The event will be held on Monday, April 27, 2009, from 3:00 p.m. to 5:00 p.m. (CDT) at The Hyatt McCormick in Conference Center Room 12D, adjacent to the McCormick Center, where the AUA meeting is being held. To participate in the event in person, please RSVP to Scott Anderson, Watson Pharmaceuticals, by Friday, April 24, via e-mail, '/>"/>

0

GOOD

Page: 1 2 3
Related medicine news :

1. Companies Continue To Add Wellness Programs, Watson Wyatt/National Business Group On Health Survey Finds
2. Mark G. Watson Named Executive Director of Radiological Society of North America
3. Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
4. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
5. Watson Acknowledges Federal Trade Commission Action Regarding AndroGel Patent Settlement
6. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
7. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
8. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
9. U.S. Workers Taking Steps to Lower Medical Costs, Watson Wyatt Survey Finds
10. China Shenghuo Announces Additional Roll-Out of 12 Ways Cosmetics Products to Watsons Stores
11. Driving Consumer Engagement Is Focus of Address by Healthfitness Chief Medical Officer at Watson Wyatt Health Care Solutions Event

Post Your Comments:

Watson to Host and Webcast Investment Community Meeting at American Urological Association Annu...( - Company to Highlight Data for its T...),Health